Aravive (ARAV) Peer Comparison
$0.04
$0.00
(0.25%)
As on 07-Feb-2024 09:30EDT
Market cap
$3 Mln
Revenue (TTM)
$7 Mln
P/E Ratio
--
P/B Ratio
1.7
Div. Yield
0 %
Edit
| Aravive (ARAV) | ImmunoGen (IMGN) | Impel Neuropharma Inc (IMPL) | Invitae Corp (NVTA) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
3 | 8,724 | 6 | -- | 1 |
Revenue ($ Mln) |
7 | 288 | 21 | 482 | -- |
Net Profit ($ Mln) |
-81.15 | -73.07 | -96.11 | -1,440.62 | -22.03 |
Net Margin (%) |
323.98 | -24.98 | -457.97 | -287.92 | -- |
RoE (%) |
-- | -21.38 | -- | -- | -- |
Price to Earnings |
-- | -- | -- | -- | -- |
Price-To-Book |
1.73 | 15.53 | 18.46 | -- | 0.44 |
Income Statement ($ Mln)
| Aravive (ARAV) | ImmunoGen (IMGN) | Impel Neuropharma Inc (IMPL) | Invitae Corp (NVTA) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
9.14 | 108.78 | 12.65 | 516.30 | 0.00 |
|
Cost of Revenue
|
66.94 | 0.18 | 6.50 | 417.26 | -- |
|
Gross Profit
|
9.14 | 108.61 | 6.16 | 99.05 | -- |
|
Operating Expenses
|
79.97 | 329.50 | 89.34 | 813.28 | 56.89 |
|
Operating Profit (EBIT)
|
-70.84 | -220.89 | -83.18 | -714.24 | -64.61 |
|
Other Income
|
-5.49 | 3.35 | -5.05 | 25.68 | 26.87 |
|
Profit before Tax
|
-76.32 | -221.71 | -106.31 | -3,151.20 | -65.15 |
|
Provision for Tax
|
4.60 | 1.22 | 23.13 | -44.90 | 0.55 |
|
Profit after Tax (Net Income)
|
-80.92 | -222.93 | -129.44 | -3,106.29 | -65.70 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-76.32 | -222.93 | -106.31 | -3,106.29 | -65.15 |
Liabilities ($ Mln)
| Aravive (ARAV) | ImmunoGen (IMGN) | Impel Neuropharma Inc (IMPL) | Invitae Corp (NVTA) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
10.66 | 155.83 | -44.16 | 101.84 | -11.85 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
30.96 | 71.25 | 110.54 | 1,744.19 | 11.69 |
|
Current Liabilities
|
20.54 | 121.86 | 22.16 | 108.09 | 20.84 |
|
Total Liabilities
|
62.15 | 348.94 | 88.55 | 1,954.12 | 20.68 |
Assets ($ Mln)
| Aravive (ARAV) | ImmunoGen (IMGN) | Impel Neuropharma Inc (IMPL) | Invitae Corp (NVTA) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
6.02 | 73.80 | 8.74 | 1,260.99 | 2.97 |
|
Current Assets
|
56.13 | 275.14 | 79.81 | 693.13 | 17.71 |
|
Total Assets
|
62.15 | 348.94 | 88.55 | 1,954.12 | 20.68 |
|
Total Debt*
|
6.27 | 15.24 | 51.19 | 1,751.00 | 2.88 |
|
Net Current Assets
|
35.86 | 182.26 | 57.65 | 585.04 | -3.13 |
Cashflow ($ Mln)
| Aravive (ARAV) | ImmunoGen (IMGN) | Impel Neuropharma Inc (IMPL) | Invitae Corp (NVTA) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-65.08 | -229.80 | -93.64 | -492.96 | -45.97 |
|
Cash Flow from Investing Activities
|
-0.01 | -1.36 | -1.38 | -174.80 | -11.61 |
|
Cash from Financing Activities
|
59.37 | 27.55 | 67.46 | 1.76 | 6.14 |
|
Net Cash Inflow / Outflow
|
-5.72 | -203.61 | 81.12 | 802.05 | 1.17 |
Ratios
Profitability Ratios
| Aravive (ARAV) | ImmunoGen (IMGN) | Impel Neuropharma Inc (IMPL) | Invitae Corp (NVTA) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-247.00 | -130.31 | -290.92 | -94.77 | -305.47 |
|
ROE (%)
|
-306.06 | -143.06 | -3,099.99 | -201.69 | -350.17 |
|
ROA (%)
|
-124.55 | -63.89 | -138.84 | -90.38 | -150.27 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-2,215.80 | -198.81 | -1,023.08 | -601.64 | 25.49 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Aravive (ARAV) | ImmunoGen (IMGN) | Impel Neuropharma Inc (IMPL) | Invitae Corp (NVTA) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.23 | 0.00 | 17.94 | 0.12 | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-112.17 | 0.00 | -69.12 | -719.59 | -1,059.23 |
|
EPS Growth (%)
|
0.29 | 0.15 | -0.64 | -6.62 | -8.74 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Aravive (ARAV) | ImmunoGen (IMGN) | Impel Neuropharma Inc (IMPL) | Invitae Corp (NVTA) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-1.03 | -5.66 | -0.69 | -0.15 | 0.00 |
|
Price / Book Value
|
7.80 | 8.10 | -2.02 | 4.46 | 0.00 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-0.51 | -4.61 | -0.97 | -2.94 | 0.20 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Aravive (ARAV) | ImmunoGen (IMGN) | Impel Neuropharma Inc (IMPL) | Invitae Corp (NVTA) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.59 | 0.10 | -1.16 | 17.19 | -0.24 |
|
Short term debt to equity ratio
|
0.21 | 0.03 | -0.03 | 0.19 | -0.06 |
|
Current Ratio
|
2.73 | 2.26 | 3.60 | 6.41 | 0.85 |
|
Quick Ratio
|
2.83 | 2.50 | 3.22 | 6.13 | -- |
|
Interest Coverage
|
-15.40 | -52.66 | -6.01 | -12.59 | -118.55 |
Operating Efficiency Ratios
| Aravive (ARAV) | ImmunoGen (IMGN) | Impel Neuropharma Inc (IMPL) | Invitae Corp (NVTA) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
0.93 | 16.53 | 58.84 | 18.62 | -- |
|
Asset Turnover
|
0.14 | 0.31 | 0.14 | 0.15 | 0.00 |
|
Receivable days
|
2.36 | 60.36 | 126.97 | 57.43 | -- |
|
Inventory Days
|
-7.76 | -13,268.33 | 316.35 | 27.97 | -- |
|
Payable days
|
31.16 | 94,120.36 | 350.32 | 15.37 | -- |
|
Cash Conversion Cycle
|
-36.56 | -107,328.32 | 93.00 | 70.04 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
